The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Prognostic factors for AITL
Marta Rodriguez-Moreno, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz University Hospital, Madrid, Spain, outlines prognostic markers for angioimmunoblastic T-cell lymphoma (AITL), a peripheral T-cell lymphoma (PTCL) subtype. Dr Rodriguez-Moreno reports that expression of B-cell markers including ICOS and CXCL13 is correlated with a poor prognosis in patients with AITL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
